InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system, announced that its Compensation Committee has approved inducement grants for a new non-executive employee. The grant consists of 18,000 shares of restricted stock, issued outside the company's 2021 Equity Compensation Plan, with a grant date of January 7, 2025.
The restricted stock will vest over three years, with one-third vesting on the first anniversary and the remaining portions vesting equally on the second and third anniversaries, contingent upon continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is specifically designed for new employees or those returning after a bona fide period of non-employment.
InspireMD (NSPR), sviluppatore del sistema di stent carotideo CGuard™ Prime, ha annunciato che il suo Comitato per la Compensazione ha approvato concessioni di incentivazione per un nuovo dipendente non esecutivo. La concessione consiste in 18.000 azioni di stock restringente, emesse al di fuori del Piano di Compensazione Azionaria 2021 dell'azienda, con una data di concessione fissata al 7 gennaio 2025.
Le azioni restrinte matureranno in tre anni, con un terzo che matura al primo anniversario e le restanti porzioni che matureranno equamente al secondo e terzo anniversario, a condizione di un'occupazione continua. Questa concessione è conforme alla Regola di Quotazione Nasdaq 5635(c)(4) ed è specificamente progettata per nuovi dipendenti o per coloro che ritornano dopo un periodo genuino di non occupazione.
InspireMD (NSPR), desarrollador del sistema de stent carotídeo CGuard™ Prime, anunció que su Comité de Compensación ha aprobado concesiones de incentivos para un nuevo empleado no ejecutivo. La concesión consiste en 18,000 acciones de stock restringido, emitidas fuera del Plan de Compensación de Capital de 2021 de la empresa, con una fecha de concesión del 7 de enero de 2025.
Las acciones restringidas adquirirán vigencia en tres años, con un tercio adquiriendo vigencia en el primer aniversario y las porciones restantes adquiriendo vigencia por igual en el segundo y tercer aniversarios, sujeto a la continuidad del empleo. Esta concesión cumple con la Regla de Cotización Nasdaq 5635(c)(4) y está específicamente diseñada para nuevos empleados o aquellos que regresen después de un período genuino de no empleo.
InspireMD (NSPR)는 CGuard™ Prime 경동맥 스텐트 시스템의 개발업체로, 보상위원회가 새로운 비임원 직원에 대한 유도 보상을 승인했다고 발표했습니다. 이 보상은 제한주식 18,000주로 구성되어 있으며, 회사의 2021년 자본 보상 계획 외부에서 발행되며, 보상 날짜는 2025년 1월 7일입니다.
제한주식은 3년에 걸쳐 수익이 발생하며, 1주년 기념일에 1/3가 수익이 발생하고 나머지 부분은 2주년 및 3주년 기념일에 각각 동일하게 수익을 발생시킵니다. 이는 계속 고용되는 것을 조건으로 합니다. 이 보상은 나스닥 상장 규칙 5635(c)(4)를 준수하며, 새 직원이나 진정한 비고용 기간 후에 복귀하는 직원들을 위해 특별히 설계되었습니다.
InspireMD (NSPR), développeur du système de stent carotidien CGuard™ Prime, a annoncé que son Comité de Rémunération a approuvé des attributions d'incitation pour un nouvel employé non-exécutif. L'attribution se compose de 18 000 actions restreintes, émises en dehors du Plan de Rémunération en Actions pour 2021 de l'entreprise, avec une date d'attribution du 7 janvier 2025.
Les actions restreintes seront mises en options sur trois ans, avec un tiers qui sera acquis lors du premier anniversaire et les portions restantes acquises également lors du deuxième et troisième anniversaires, sous réserve de la poursuite de l'emploi. Cette attribution est conforme à la Règle de Cotation Nasdaq 5635(c)(4) et est spécifiquement conçue pour les nouveaux employés ou ceux qui reviennent après une période authentique de non-emploi.
InspireMD (NSPR), Entwickler des CGuard™ Prime Karotisstentsystems, gab bekannt, dass sein Vergabekomitee Zulassungen für einen neuen nicht-executiven Mitarbeiter genehmigt hat. Die Zulassung besteht aus 18.000 Aktien mit eingeschränkter Übertragbarkeit, die außerhalb des Equity Compensation Plans 2021 des Unternehmens ausgegeben werden, mit einem Zieldatum der Genehmigung am 7. Januar 2025.
Die eingeschränkten Aktien werden über drei Jahre vesten, wobei ein Drittel am ersten Jahrestag vestet und die verbleibenden Anteile gleichmäßig am zweiten und dritten Jahrestag vesten, vorausgesetzt die Anstellung bleibt bestehen. Diese Genehmigung entspricht der Nasdaq-Listing-Regel 5635(c)(4) und ist speziell für neue Mitarbeiter oder solche, die nach einer echten Periode ohne Beschäftigung zurückkehren, konzipiert.
- None.
- None.
MIAMI, Feb. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to one new non-executive employee in the amount of 18,000 shares of restricted stock outside of InspireMD’s 2021 Equity Compensation Plan, with a grant date as of January 7, 2025, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock vests over a three-year period, with one-third vesting on the first anniversary of the grant and the remainder vesting in two equal installments on the second and third anniversaries of the grant date, subject to continued employment with InspireMD as of such vesting dates.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.
We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation, including potential U.S. commercial launch. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities; substantial doubt about our ability to continue as a going concern; significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders’ ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com
investor-relations@inspiremd.com
FAQ
How many restricted shares did InspireMD (NSPR) grant in their January 2025 inducement grant?
What is the vesting schedule for NSPR's January 2025 inducement grant?
Under which compensation plan were NSPR's January 2025 inducement shares granted?
When was the grant date for NSPR's latest inducement grant announcement?
